Cubist Systematic Strategies’s Orphazyme A/S ORPH Stock Holding History

Cubist Systematic Strategies’s Portfolio ORPH Stock Details ORPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-490	Closed	-$4K	–	3200
2021 Q1	$4K	Buy	+490	New	+$6.03K	﹤0.01%	2794

Other funds holding ORPH

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BAM

Blueshift Asset Management Red Bank, New Jersey $432M AUM 13.14% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Cubist Systematic Strategies's ORPH Position: Q2 2021 in Review

Cubist Systematic Strategies sold out of Orphazyme A/S (ORPH) in Q2 2021, closing a stake of 490 shares — an estimated $4K sold.

Cubist Systematic Strategies first reported a position in ORPH in Q1 2021 and held it in 1 quarter. The position peaked at $4K in Q1 2021. 20 funds tracked by Wall St. Rank hold ORPH as of Q2 2021.

Cubist Systematic Strategies reported no remaining Orphazyme A/S position as of Q2 2021 after selling out during the quarter.
Cubist Systematic Strategies sold 490 Orphazyme A/S shares in Q2 2021, an estimated $4K.
Cubist Systematic Strategies first reported a position in Orphazyme A/S in Q1 2021 and held it in 1 quarter.
Cubist Systematic Strategies's Orphazyme A/S position peaked at $4K in Q1 2021.
20 funds tracked by Wall St. Rank held Orphazyme A/S as of Q2 2021.

Based on Cubist Systematic Strategies's 13F filing for Q2 2021, filed 16 Aug 2021.